Diagnostics and medical devices lifted second-quarter revenue to $12.593 billion, while net income fell to $928 million; Abbott reaffirmed 2026 comparable sales growth guidance and raised adjusted EPS guidance.
Abbott reported second-quarter sales of $12.593 billion, up 13.0% on a reported basis and 4.8% on a comparable basis, while net income fell to $928 million, or $0.53 per share, from $1.779 billion, or $1.01 per share, a year earlier. Adjusted diluted EPS rose to $1.31 from $1.26. The company reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised its full-year 2026 adjusted diluted EPS range to $5.45 to $5.60 from $5.38 to $5.58, while projecting third-quarter 2026 adjusted diluted EPS of $1.38 to $1.46. Diagnostics sales rose 42.3% on a reported basis and medical devices sales increased 9.0%, while nutrition sales declined 3.1%.